Monitoring potential iron toxicity in iv iron supplementation used for the treatment of anemia in CKD patients

The increased use of iv iron supplements among CDK-ESRD patients has also raised the demand for quality control of the pharmaceutical formulations as potential source of labile (toxic) iron in patients' plasma



The FeROS™ LPI assay is a CE marked technology designed for the measurement of labile iron in fluids, particularly in plasma, where it is referred as Labile Plasma Iron (LPI). The assay provides a measure of potentially toxic iron in plasma which is redox active (labile) as it is not transferrin-bound. The assay can provide a measure of labile iron presence in the formulation and in plasma following iv administration.

The FeROS™ LPI assay can be used for assessing:
1. Product stability (different available formulations and others in R&D):
Shelf and in human plasma. Continuous follow-up of labile plasma iron levels in patients during and post iv iron administration as measure of product safety
2. Monitoring the appearance of LPI following oral and iv iron supplementation.

For more information:
Visit us at www.aferrix.com
Contact us at info@aferrix.com